PLUVICTO®▼ and PSMA:
A new therapeutic option for eligible mCRPC patients
Tuesday 25 October 2022 | 18:00 – 19:00 BST

This promotional webinar is organised and funded by Advanced Accelerator Applications, a Novartis company, and is intended for GB Healthcare Professionals only.

UK | October 2022 | AAA-PSMA-UK-0065

​

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

​

Adverse events should be reported. Reporting forms and information can be found at  https://yellowcard.mhra.gov.uk (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

​

 

Pluvicto is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.